TCGA-P3-A6T7-01A-11R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.111187215
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- MYC_TARGETS_V1+0.410
- CHOLESTEROL_HOMEOSTASIS+0.400
- INTERFERON_GAMMA_RESPONSE+0.380
- MYC_TARGETS_V2+0.380
- OXIDATIVE_PHOSPHORYLATION+0.300
- TNFA_SIGNALING_VIA_NFKB+0.290
- NOTCH_SIGNALING+0.280
- MTORC1_SIGNALING+0.260
- ESTROGEN_RESPONSE_LATE+0.250
Top 10 suppressed
- MYOGENESIS-0.220
- PROTEIN_SECRETION-0.160
- ANGIOGENESIS-0.130
- HEDGEHOG_SIGNALING-0.130
- UV_RESPONSE_DN-0.120
- MITOTIC_SPINDLE-0.110
- WNT_BETA_CATENIN_SIGNALING-0.110
- ALLOGRAFT_REJECTION-0.100
- PANCREAS_BETA_CELLS-0.100
- KRAS_SIGNALING_UP-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-7099-01A-41R-2016-07 | — | — | 0.809 |
| 2 | TCGA-MT-A51W-01A-21R-A266-07 | — | — | 0.794 |
| 3 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.780 |
| 4 | TCGA-E2-A14Y-01A-21R-A12D-07 | — | E | 0.776 |
| 5 | 6794CB9F-5326-4F57-B2E2-5D877C03F5D4 | — | — | 0.764 |
| 6 | SRR8942992 | — | — | 0.762 |
| 7 | SRR8942975 | — | — | 0.762 |
| 8 | TCGA-BA-A6DD-01A-12R-A31N-07 | — | — | 0.762 |
| 9 | SRR35579811 | — | B | 0.757 |
| 10 | C3N-03425 | — | cohortSQ1 | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |